Clinical Trials Browser

dalotuzumab × Thoracic × Clear all

NCT00869752 2023-08-04

MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 1/2 Completed

Lung Neoplasms

NCT00654420 2018-08-08

A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)

Phase 2 Completed

95 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT00951444 2016-07-06

Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00729742 2016-04-04

Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT00799240 2014-11-07

IMPACT

Phase 2 Completed

Insulin-Like Growth Factor I, Resistance To, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pleural Effusion